5'-UTR CONTAINING mRNA CONSTRUCTS WITH IMPROVED TRANSLATION EFFICIENCY AND VACCINE COMPOSITIONS COMPRISING SAME

TWI945950BActive Publication Date: 2026-11-11GC BIOPHARMA CORP
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
TW114127321
Authority / Receiving Office
TW · TW
Patent Type
Patents
Current Assignee / Owner
Priority Date
2023-06-01
Filing Date
2024-05-31
Publication Date
2026-11-11
Estimated Expiration
2044-05-30

AI Technical Summary

Technical Problem

Current influenza vaccines require annual administration due to antigenic drift and have challenges with cross-protective immunity across different subtypes, and mRNA vaccines face issues with inefficient translation and stability, limiting their effectiveness and safety.

Method used

Development of an mRNA construct with improved 5'-UTR sequences and a vaccine composition that includes a specific motif and codon-optimized signal sequence to enhance translation efficiency and stability, encoding antigenic polypeptides or immunogenic fragments.

Benefits of technology

The improved mRNA construct achieves higher protein expression efficiency and immune response, providing potential for a more effective and safer influenza vaccine with cross-protective immunity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure TWG2TB001920702_001
    Figure TWG2TB001920702_001
  • Figure TWG2TB001920702_002
    Figure TWG2TB001920702_002
  • Figure TWG2TB001920702_003
    Figure TWG2TB001920702_003
Patent Text Reader

Abstract

This invention relates to mRNA constructs comprising a 5'-UTR with improved translation efficiency and vaccine compositions comprising the construct, and more specifically, to mRNA constructs containing a 5'-UTR that have been engineered to include specific motifs, codon-optimized signal sequences, and antigen-coding sequences, and to vaccine compositions comprising the construct. The mRNA constructs according to the invention comprise a 5'-UTR with improved translation efficiency, which can effectively induce the expression of antigenic peptides and is useful for vaccine development because it is expected to increase immunogenicity as a vaccine.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] The present invention relates to an mRNA construct comprising a 5'-UTR with improved translation efficiency and a vaccine composition comprising the construct, and more particularly, to an mRNA construct comprising a 5'-UTR with improved translation efficiency that has been engineered to include a specific motif, a codon-optimized signal sequence and an antigen-coding sequence, and a vaccine composition comprising the construct. [Previous Technology]

[0002] Vaccines have been used since the 16th century. In 1798, an article on smallpox vaccine first clearly reported the use of vaccines. Since then, many different types of vaccines have been developed to treat a variety of diseases and to prevent diseases (Pollard, AJ et al., Nat Rev Immunol Vol. 21, pp. 83-100, 2021).

[0003] Vaccines can be classified into live vaccines (live or attenuated), inactivated vaccines (dead), toxoid vaccines, subunit vaccines, VLP vaccines, other membrane-based vaccines, protein-polysaccharide conjugate vaccines, viral vector-based vaccines, and gene vaccines.

[0004] Live vaccines were used for the first time for smallpox, toxoid vaccines for the first time for diphtheria, subunit vaccines for the first time for anthrax, VLP vaccines for the first time for hepatitis B, other membrane vaccines for the first time for group B meningococcus, protein-polysaccharide conjugate vaccines for the first time for influenza B, viral vector vaccines for the first time for Ebola, and mRNA vaccines for the first time for SARS-CoV-2 (Pollard, AJ et al, Nat Rev Immunol Vol. 21, pp. 83-100, 2021).

[0005] Influenza virus (IV) is a single-stranded, negative-sense RNA virus composed of eight RNA segments with a single negative strand. It expresses 10 to 13 different proteins and belongs to the Orthomyxoviridae family. Based on the antigenicity of its nucleoprotein (NP) and matrix (M) proteins, it is classified into types A, B, and C. These nucleoproteins and matrix proteins are structural proteins attached to the surface of the virus (Lamb RA et al., Fields Virology, pp. 1487-1531, 2001), and types A and B are known to be primarily pathogenic in humans. Type A can infect not only humans but also pigs and birds. Type B's sole host is humans.

[0006] Influenza viruses are composed of two surface glycoproteins (surface antigens): hemagglutinin and neuraminidase. Based on the type and combination of hemagglutinin (an antigenic protrusion that binds to a host cell receptor (sialic acid)) and neuraminidase (which cleaves sialic acid to release the sialic acid-bound virus into the cell), influenza viruses are classified into several subtypes. These subtypes are mainly classified under influenza A. Currently, there are 18 different hemagglutinins, H1 to H18, and 11 different neuraminidases, N1 to N11, which theoretically can combine to form 198 different influenza A subtypes. Influenza B viruses are divided into two strains based on antigen type: Victoria and Yamagata.

[0007] Influenza is characterized by antigenic variation, a typical feature of RNA viruses, which mutates slightly or significantly almost every year. Antigenic drift occurs almost annually, especially for influenza A and B, causing seasonal epidemics. Therefore, the World Health Organization (WHO) compiles information on viral epidemics and releases vaccine recommendations for the current season around February each year. Antigenic drift is a point mutation within the same subtype, which produces new hemagglutinins or neuraminidases with slightly altered antigenicity through minor antigenic variations. Antigenic translocation is a subtype change, such as H3N2 → H2N2, which produces a new virus. In addition to these two modifications, culturing in embryonic eggs can induce mutations that lead to antigenic differences, mutations not found in cell cultures; therefore, vaccines using viruses cultured in mammalian cells are preferred.

[0008] Due to antigenic drift and a shelf life of less than one year, influenza vaccines should be administered annually. In the Northern Hemisphere, due to the length of the flu season (December to April) and the vaccine's shelf life (average 6 months), it is recommended to get vaccinated between October and December each year.

[0009] Currently, influenza vaccines include inactivated (killed) vaccines and live attenuated influenza vaccines (LAIV). Inactivated vaccines are produced by inactivating the virus cultured in fertilized eggs (hatching eggs) with formalin or by culturing the virus in cell cultures with formalin, harvesting the surface antigen, and then administering it intramuscularly (im) as the vaccine antigen. Live attenuated vaccines are administered via nasal spray.

[0010] Inactivated vaccines include whole-virus vaccines, which use the whole virus; split vaccines (subviral vaccines), which are prepared by removing the viral envelope using Triton X-100; and subunit vaccines, which are prepared by purifying hemagglutinin and neuraminidase components. Hemagglutinin and neuraminidase are antigens that directly trigger a neutralizing antibody response, with hemagglutinin being the primary neutralizing antigen. Whole-virus vaccines are not widely used in South Korea or globally, and are only available in a few countries or regions because they can cause side effects in children. On the other hand, component vaccines (such as split vaccines or subunit vaccines) are very safe, effective, and the most commonly used.

[0011] In addition, vaccines containing immune adjuvants (such as MF-59) or virosome vaccines (which form virus-like vesicles) have been developed to enhance immune responses and are being used in some countries or regions. To provide adequate immune defense against influenza virus infection, especially for preventative or therapeutic purposes, it is necessary to incorporate effective and safe adjuvants into vaccines.

[0012] Antibodies acquired through natural infection or vaccination against a specific subtype or influenza virus usually do not produce protective antibodies against other types or subtypes of influenza virus, and may be insufficiently immunogenic against novel variants within a single antigen.

[0013] Getting vaccinated every year is a challenge because the flu virus undergoes both major and minor mutations every year, which causes the epidemic to change every year, so it is difficult to expect the previous year's vaccine to provide protection.

[0014] Current seasonal influenza vaccines only provide protective immunity against the viral strain used in the vaccine. Therefore, there is a need to develop an affordable and effective influenza vaccine that can provide sufficient cross-protective immunity across various subtypes. To develop a universal vaccine with cross-protective immunity, an antigen with minimal antigenic variation or a method for stimulating mucosal immunity is required. One such method is to use one or more HA2 domains of HA with low antigenic variation as the vaccine antigen (Korean Patent No. 10-1637955).

[0015] On the other hand, it has been reported that when DNA or RNA encoding a target gene is injected directly into an animal, the target gene will be expressed in the living animal and this expression will confer immunity, thus the development of gene vaccines has begun (Wolff JA et al. Science, 247: 1465-8, 1990).

[0016] DNA and mRNA can be used as nucleic acid molecules for the active pharmaceutical ingredient (API) in gene vaccines, and DNA is known to be relatively stable and easier to handle compared to mRNA. However, in the case of DNA, there is a potential risk that DNA fragments administered to a patient's genome may be inserted into unwanted locations, leading to gene damage. Furthermore, unwanted anti-DNA antibodies may develop. Another issue is that the expression levels of peptides or proteins expressed via DNA administration and subsequent transcription / translation are limited. The presence of specific transcription factors that regulate DNA transcription has a significant impact on the expression levels of administered DNA, and in the absence of specific transcription factors, DNA transcription cannot produce sufficient amounts of mRNA; therefore, the extent of translated peptides or proteins is limited.

[0017] On the other hand, when mRNA is used as an API for gene delivery, it does not require transcription and can synthesize proteins directly in the cytoplasm, unlike DNA which needs to enter the nucleus. This eliminates the risk of getting stuck in the cell's chromosomes and causing unwanted genetic damage. Furthermore, it has a shorter half-life than DNA, thus avoiding long-term gene modification (Sayour EJ, et al., J Immunother Cancer Vol. 3, 13, 2015). Typical mRNA vaccines, upon delivery to cells, are activated to express the target protein for only a short time and are destroyed by enzymatic reactions within a few days, preserving a specific immune response to the expressed target antigen (protein).

[0018] Furthermore, when mRNA is used as a gene delivery tool, it does not need to cross the nuclear membrane to function; it only needs to cross the cell membrane. Therefore, it can express the same amount of target protein as DNA in a smaller quantity than DNA. In addition, mRNA itself has immunostimulatory properties, so a smaller amount of mRNA is needed to produce the same immune effect as DNA. By using mRNA instead of DNA for gene vaccination, the risks of unwanted genome integration and the generation of anti-DNA antibodies are minimized or avoided. However, mRNA is considered a rather unstable molecule that can be easily degraded by ubiquitous ribonucleases.

[0019] Despite significant progress over the years, challenges remain in the field of effective methods for mRNA vaccination that can elicit an adaptive immune response, such as inefficient mRNA translation due to premature antigen degradation or inefficient release of mRNA from cells. Furthermore, there is an urgent need to reduce the dosage of mRNA vaccines to minimize potential safety concerns and make vaccines more affordable for the developing world.

[0020] Delivering nucleic acids to elicit the desired response in biological systems presents many challenges. While nucleic acid-based therapies, such as vaccines, are promising, there is still a need to deliver nucleic acids more efficiently to appropriate sites within cells or organisms to realize this potential.

[0021] However, the use of nucleic acids for therapeutic and preventative purposes currently faces two challenges. First, naked mRNA is readily digested by nucleases in plasma. Second, naked mRNA has limited ability to enter the intracellular compartments where relevant translation occurs. To address these issues, attempts have been made to use lipid nanoparticles (LNPs) composed of various lipid components (such as neutral lipids, cholesterol, PEG, polyethylene glycol-modified lipids, or oligonucleotides) and cationic lipids to block the degradation of mRNA in plasma and promote cellular uptake of nucleic acids.

[0022] In addition, mRNA vaccines containing several types of lipid nanoparticles related to influenza vaccines have been reported (Korean Patent Publication No. 10-2018-0096591). [Summary of the Invention]

[0023] Therefore, the inventors of the present invention have made sincere efforts to solve the above-mentioned problems and developed mRNA constructs containing 5'-UTRs with improved translation efficiency. They have also demonstrated that by selecting artificial nucleic acid molecules that do not produce secondary structures, have low uridine content, and do not contain sequences that reduce stability in a combination of artificial nucleic acid molecules of 30 bp in length, it is possible to obtain 5'-UTRs with improved translation efficiency. Furthermore, the mRNA constructs containing these sequences perform better as vaccines, thus completing the present invention.

[0024] One object of the present invention is to provide an mRNA construct encoding an antigenic polypeptide or an immunogenic fragment thereof.

[0025] Another object of the present invention is to provide a vaccine composition comprising an mRNA construct.

[0026] To achieve the above objectives, the present invention provides an mRNA construct encoding an antigenic polypeptide or an immunogenic fragment thereof, wherein the mRNA construct comprises, in order from 5' to 3', a) a 5'-cap structure; b) a 5'-untranslated region (5'-UTR) polynucleotide, represented by a nucleic acid sequence according to formula (I) or (II): formula (I): AG[N22]GCCACC, formula (II): AGGA[N19]RGCCACC, where R represents A, G or U; c) a polynucleotide encoding a signal peptide; d) a polynucleotide encoding an antigenic polypeptide or an immunogenic protein thereof; e) a 3'-untranslated region (3'-UTR); and f) a poly(A) tail or poly(A) tail sequence consisting of 10 to 1000 adenine (A) moieties.

[0027] The present invention further provides an influenza vaccine composition comprising an mRNA construct.

[0028] The present invention further provides the use of the vaccine composition for the prevention of influenza.

[0029] The present invention further provides a method for preventing influenza, including the step of administering a vaccine composition.

[0030] The present invention further provides the use of the vaccine composition in the preparation of an agent for the prevention of influenza.

Implementation Method

[0039] Unless otherwise defined, all technical and scientific terms used herein shall have the same meaning as commonly understood by one of ordinary skill in the art. Generally, the nomenclature and experimental methods described herein are well-known and commonly used in the art.

[0040] In this invention, it is sought to determine that an mRNA construct containing a 5'-UTR with improved translation efficiency can be used to express influenza antigenic proteins with higher efficiency than wild-type mRNA.

[0041] That is, in one embodiment of the present invention, it was found that the expression efficiency of influenza antigen protein was significantly improved by using an mRNA construct comprising a 5'-UTR polynucleotide with improved translation efficiency (Figure 1) (Figures 3 to 6).

[0042] Therefore, from one perspective, the present invention relates to,

[0043] An mRNA construct encoding an antigenic polypeptide or an immunogenic fragment thereof, comprising: a) a 5'-cap structure in the order from 5' to 3'; b) a 5'-untranslated region (5'-UTR) polynucleotide, represented by a nucleic acid sequence according to formula (I) or (II): formula (I): AG[N22]GCCACC, formula (II): AGGA[N19]RGCCACC, wherein R represents A, G or U; c) a polynucleotide encoding a signal peptide; d) a polynucleotide encoding an antigenic polypeptide or an immunogenic protein thereof; e) a 3'-untranslated region (3'-UTR); and f) a poly(A) tail or poly(A) tail sequence consisting of 10 to 1000 adenine (A) moieties.

[0044] The 5'-cap (CAP) of natural mRNA accompanies nuclear export, increasing mRNA stability and binding to mRNA cap-binding protein (CBP). Through association between poly(A)-binding protein and CBP, mature circular mRNA species are formed, leading to mRNA stability at the cellular and translational levels. During mRNA splicing, the cap further helps remove introns near the 5' end.

[0045] In this invention, the 5'-cap is typically a modified nucleotide (cap analogue) added to the 5' end of an mRNA molecule, particularly a guanine nucleotide. Preferably, a 5'-5'-triphosphate bond (also known as m7GpppN) is used to add the 5'-cap. Other examples of 5'-cap structures include glycerol groups, reverse deoxybasic (base-free) residues (partially), 4',5'-methylene nucleotides, 1-(β-D-erythrofuranosyl) nucleotides, 4'-thionucleotides, carbocyclic nucleotides, 1,5-anhydrous hexanol nucleotides, L-nucleotides, α-nucleotides, modified base nucleotides, threo-pentofuranosyl nucleotides, and acyclic 3',4'-seconucleotides. Nucleotide), acyclic 3,4-dihydroxybutyl nucleotide, acyclic 3,5-dihydroxypentyl nucleotide, 3'-3'-reverse nucleotide moiety, 3'-3'-reverse non-base moiety, 3'-2'-reverse nucleotide moiety, 3'-2'-reverse non-base moiety, 1,4-butanediol phosphate, 3'-aminophosphate, hexyl phosphate, aminohexyl phosphate, 3'-phosphate, 3'-thiophosphate, dithiophosphate, or bridged or non-bridged methylphosphonate moiety.

[0046] These modified 5'-cap structures can be used to modify the mRNA sequence of the synthetic nucleic acid molecules of the present invention.

[0047] Other modified 5'-cap structures that can be used in this invention include CAP1 (additional methylation of the ribose of the nucleotide adjacent to m7GpppN), CAP2 (additional methylation of the ribose of the second nucleotide downstream of m7GpppN), CAP3 (additional methylation of the ribose of the third nucleotide downstream of m7GpppN), CAP4 (additional methylation of the ribose of the fourth nucleotide downstream of m7GpppN), ARCA (anti-reverse cap analog), modified ARCA (e.g., phosphate thioester modified ARCA), inosine, N1-methyl-guanosine, 2'-fluoro-guanosine, 7-deazono-guanosine, 8-sideoxy-guanosine, 2-amino-guanosine, LNA-guanosine, and 2-azido-guanosine.

[0048] In this invention, the 5'-cap structure can be synthesized from chemical RNA or formed by in vitro transcription of RNA using cCAP analogs (co-transcriptional capping), or the cap structure can be formed in vitro using capping enzymes (e.g., commercially available capping kits).

[0049] As used herein, a cap analog refers to a non-polymeric dinucleotide with a cap function that, when a cap is introduced at the 5' end of an RNA molecule, facilitates translation or localization and / or prevents degradation of the RNA molecule. Non-polymeric means that the cap analog lacks a 5' triphosphate group and therefore binds only at the 5' end, and cannot be extended in the 3' direction by template-dependent RNA polymerase.

[0050] Cap analogs may include chemical structures selected from, but not limited to, the group consisting of: m7GpppA, m7GpppAmpG, dimethylated cap analogs, trimethylated cap analogs (e.g., m2,2,7GpppA), dimethylated symmetrical cap analogs (e.g., m7Gpppm7A) or anti-reverse cap analogs (e.g., ARCA; m7,2'OmeGpppA, m7,2'dGpppA, m7,3'OmeGpppA, m7,3'dGpppA, and their tetraphosphate derivatives).

[0051] Other cap analogues have been previously described (US 7,074,596, WO 2008 / 016473, WO 2008 / 157688, WO 2009 / 149253, WO 2011 / 015347 and WO 2013 / 059475).

[0052] In this invention, the 5'-cap structure may be selected from, but is not limited to, the group consisting of m7GpppAmpG, m7,3'OmeApppG and m7GpppA.

[0053] In this invention, 5'-UTR can be any of the sequences represented by SEQ ID NO: 1 to 34 in Table 1 below, more preferably any of the group consisting of SEQ ID No: 1, 2, 15, 28 and 30, but is not limited thereto.

[0054] [Table 1] SEQ ID NO. name sequence 1 GC00 AGGAGGACUGGACUGGACUGGACUGCCACC 2 GC01 AGGAGAAGAGAGAAAAGUAAAAUAGCCACC 3 GC02 AGGAGUAAAAGUAAAAUAGUAAAAGCCACC 4 GC03 AGGAGAAAAGAAAGAGUAAAAUAGGCCACC 5 GC04 AGGAUUAAAAAUAGAAAGAAUAAGGCCACC 6 GC05 AGGACAACAAACAAAAACAAACUAGCCACC 7 GC06 AGGACAGAGCACUAGAACAAAACAGCCACC 8 GC07 AGGACCACUCUCAACCAAAACCUAGCCACC 9 GC08 AGGAGACACUAACACCCCGACCGAGCCACC 10 GC09 AGGACCGGAACACAAAAACUAGCAGCCACC 11 GC10 AGGAACUACACUAGCCACUAAACAGCCACC 12 GC11 AGGACAACUAGACAGAGACACCGAGCCACC 13 GC12 AGGACACAACACCCAGACCACCGAGCCACC 14 GC13 AGGACACAACUACCGAACUACUCAGCCACC 15 GC14 AGGAGAACUAGUACCCACCCGACAGCCACC 16 GC15 AGGAGAGAAAAAAACAACUACACAGCCACC 17 GC16 AGGAGAAACAACUAGGACCACAGAGCCACC 18 GC17 AGGACCUAAAACACCUCGACAGCAGCCACC 19 GC18 AGGAAAAAACUCACCUCUCAGACAGCCACC 20 GC19 AGGAGAGAAACUACACAGACUAGAGCCACC 21 GC20 AGGAACAACAGACUCACUCACUCAGCCACC 22 GC21 AGGAAAACUAAACAGAACCUAACAGCCACC 23 GC22 AGGAACAGAGAACACUAGAGAGCAGCCACC 24 GC23 AGGACCACACAGACCCACCUACUAGCCACC 25 GC24 AGGAAACCGACUAAAAACCCUCUAGCCACC 26 GC25 AGGAACAACACCAGCAGAACUCGAGCCACC 27 GC26 AGGAACAACAGUCGUAACCCUCUAGCCACC 28 GC27 AGGACCCUAACCAAACCCACUCUAGCCACC 29 GC28 AGGACACAACUCUACCCGACUACAGCCACC 30 GC29 AGGAACACAGUCAGCACCAACACAGCCACC 31 GC30 AGGACACUCAGACAACCCACACUAGCCACC 32 GC31 AGGACCUCAAAAAAAAACUCUAGCCACC 33 GC32 AGGACAACAGCUCACACCCCCCUAGCCACC 34 GC33 AGGACCCAGAACCCACCUAACAGAGCCACC

[0055] As used herein, the term "UTR" refers to a "non-translated region" located upstream (5') and / or downstream (3') of the coding region of a nucleic acid molecule described herein, and is therefore typically located on one side of the coding region. Thus, the term "UTR" typically includes a 3' non-translated region ("3'-UTR") and a 5'-non-translated region ("5'-UTR"). A UTR typically contains or may consist of a nucleic acid sequence that has not been translated into a protein. Typically, a UTR includes "regulatory elements".

[0056] The term "regulatory element" refers to a transcribed nucleic acid sequence that has gene regulatory activity, is operatively (cis or trans) linked, and particularly has the ability to influence transcription or translation. This term includes promoters, enhancers, internal ribosome entry sites (IRES), introns, leader sequences, transcription termination signals (such as polyadenylation signals and poly-U sequences), and other regulatory elements of expression. Regulatory elements may function constitutively or in a time-specific and / or cell-specific manner. Optionally, regulatory elements may function through interactions with regulatory proteins (e.g., mobilization and binding), wherein said regulatory proteins can regulate (induce, enhance, reduce, eliminate, or prevent) expression, particularly gene transcription.

[0057] The UTR is preferably "operably connected" to the coding region, i.e. arranged in a functional relationship, in such a way as to control (i.e. mediate or regulate, preferably enhance) the expression of the coding sequence.

[0058] In this invention, the term "5'-UTR" refers to a portion of a nucleic acid molecule located at the 5' (i.e., "upstream") of an open reading frame that is not translated into a protein. In the context of this invention, a 5'-UTR begins at the transcription start site and ends one nucleotide before the start codon of the open reading frame.

[0059] The 5'-UTR may contain elements that regulate gene expression, i.e., so-called "regulatory elements." Such regulatory elements may be, for example, ribosome binding sites. The 5'-UTR may be modified by post-transcriptional modification, for example by adding a 5'-cap. Therefore, the 5'-UTR may preferably correspond to the nucleic acid, particularly the sequence of mature mRNA, located between the 5'-cap and the start codon, more specifically the nucleotide at the 3' end of the 5'-cap, preferably the nucleotide at the 5' end of the start codon (transcription start site) of the protein-coding sequence located directly after the 3' end of the 5'-cap, and preferably the nucleotide directly before the 5' end of the start codon (transcription start site) of the protein-coding sequence.

[0060] The nucleotide located directly at the 3' end of the 5' cap of mature mRNA typically corresponds to the transcription start site. The length of the 5'UTR is typically less than 500, 400, 300, 250, or less than 200 nucleotides. In some instances, its length can be 10, 20, 30, or 40 or more nucleotides, preferably 10 or 50 or fewer nucleotides.

[0061] In this invention, the signal peptide may be derived from antigenic polypeptides, immunoglobulin E (IgE) or tissue plasminogen activator (tPA), but is not limited thereto.

[0062] In this invention, the signal peptide of the antigenic polypeptide can be represented by the following amino acid sequences: SEQ ID NO: 72 (MKAIIVLLMVVTSNA), SEQ ID NO: 73 (MKXIIALSXILCLVFA, where X is T, A, Y, or N) or SEQ ID NO: 77 (MKAILVVXLYTFTTANA, where X is L or M). More preferably, it can be represented by the following amino acid sequences, but not limited to: SEQ ID NO: 72 (MKAIIVLLMVVTSNA), SEQ ID NO: 74 (MKTIIALSYILCLVFA), SEQ ID NO: 75 (MKTIIALSNILCLVFA), SEQ ID NO: 76 (MKAIIALSNILCLVFA), SEQ ID NO: 78 (MKAILVVMLYTFTTANA) or SEQ ID NO: 79 (MKAILVVLLYTFTTANA).

[0063] In this invention, the signal peptide of IgE can be represented by the amino acid sequence of SEQ ID NO: 80, but is not limited thereto.

[0064] In this invention, the signal peptide of tPA can be represented by the amino acid sequence of SEQ ID NO: 81, but is not limited thereto.

[0065] [Table 2] Signal peptide sequence SEQ ID NO. name sequence 72 B_Ya_Vic_HA_WT_AA MKAIIVLLMVVTSNA 73 A_H3N2_HA_WT_AA_Norm MKXIIALSXILCLVFA 74 A_H3N2_HA_WT_AA_P MKTIIALSYILCLVFA 75 A_H3N2_HA_WT_AA_22 MKTIIALSNILCLVFA 76 A_H3N2_HA_WT_AA_25 MKAIIALSNILCLVFA 77 A_H1N1_HA_WT_AA_Norm MKAILVVXLYTFTTANA 78 A_H1N1_HA_WT_AA_P MKAILVVMLYTFTTANA 79 A_H1N1_HA_WT_AA_20 MKAILVVLLYTFTTANA 80 IgE_WT_AA MDWTWILFLVAAATRVHS 81 tPA_WT_AA MDAMKRGLCCVLLLCGAVFVSA

[0066] In this invention, the polynucleotide encoding the signal peptide can be codon-optimized, preferably any of the sequences represented by SEQ ID NO: 39 to 50, but not limited thereto.

[0067] In this invention, the polynucleotide encoding the 5'-UTR and the signal peptide can be any one selected from, but not limited to, the group consisting of: (i) polynucleotides encoding the 5'-UTR of SEQ ID NO: 1 and the signal peptide of SEQ ID NO: 39; (ii) polynucleotides encoding the 5'-UTR of SEQ ID NO: 1 and the signal peptide of SEQ ID NO: 42; (iii) polynucleotides encoding the 5'-UTR of SEQ ID NO: 1 and the signal peptide of SEQ ID NO: 45; (iv) polynucleotides encoding the 5'-UTR of SEQ ID NO: 1 and the signal peptide of SEQ ID NO: 48; (v) polynucleotides encoding the 5'-UTR of SEQ ID NO: 28 and the signal peptide of SEQ ID NO: 39; (vi) polynucleotides encoding the 5'-UTR of SEQ ID NO: 28 and the signal peptide of SEQ ID NO: 42; (vii) polynucleotides encoding the 5'-UTR of SEQ ID NO: 28 and the signal peptide of SEQ ID NO: 45; (viii) polynucleotides encoding the 5'-UTR of SEQ ID NO: 28 and the signal peptide of SEQ ID NO: 45; (viii) polynucleotides encoding the 5'-UTR of SEQ ID NO: 28 and the signal peptide of SEQ ID NO: 45; (ix) a polynucleotide encoding the 5'-UTR of SEQ ID NO: 28 and the signal peptide of SEQ ID NO: 48; (x) a polynucleotide encoding the 5'-UTR of SEQ ID NO: 1 and the signal peptide of SEQ ID NO: 41; (x) a polynucleotide encoding the 5'-UTR of SEQ ID NO: 1 and the signal peptide of SEQ ID NO: 44; (xi) a polynucleotide encoding the 5'-UTR of SEQ ID NO: 1 and the signal peptide of SEQ ID NO: 47; and (xii) a polynucleotide encoding the 5'-UTR of SEQ ID NO: 1 and the signal peptide of SEQ ID NO: 50.

[0068] In this invention, according to one embodiment of the invention, the term "GC00-WT-HA" is an abbreviation for 5'-UTR signal peptide-ORF, meaning that although the same expression is used, different strains have different 5'-UTR, signal peptide and ORF sequence compositions, as described in Tables 4 to 7 of the invention.

[0069] In this invention, the antigenic polypeptide may be one or more selected from, but not limited to, the group consisting of: tumor antigen, pathogenic antigen, autoantigen, alloantigen and allergenic antigen.

[0070] As used herein, the term "tumor antigen" refers to an antigenic (poly)peptide or protein derived from or associated with a tumor (preferably a malignant tumor) or cancer. The terms "cancer" and "tumor" are used interchangeably herein and refer to a tumor characterized by uncontrolled and typically rapid cell proliferation attempting to invade surrounding tissues and metastasize to distant body sites. These terms include both benign and malignant tumors. Malignant tumors are typically characterized by degeneration (anaplasia), invasiveness, and metastasis; benign tumors typically lack these characteristics. The terms "cancer" and "tumor" specifically refer to cancers of the blood and lymphatic system, as well as growths characterized by tumor growth. "Tumor antigens" are generally derived from tumors / cancer cells, preferably mammalian tumors / cancer cells, and may be located within or on the surface of tumor cells derived from mammals (preferably mammals, especially humans) or tumors such as systemic tumors or solid tumors. "Tumor antigens" typically include tumor-specific antigens (TSA) and tumor-associated antigens (TAA). TSA is typically caused by tumor-specific mutations and is specifically expressed by tumor cells. TAAs are more common and are typically found in both tumor and "normal" (healthy, non-tumor) cells.

[0071] In this invention, the tumor antigen can be a tumor-associated protein or nucleic acid sequence, wherein each nucleic acid sequence encodes a different peptide or protein; and at least one of the nucleic acid sequences can encode 5T4, 707-AP, 9D7, AFP, AlbZIP HPG1, α-5-β-1-integrin, α-5-β-6-integrin, α-actin-4 / m, α-methylacetylated coenzyme A racemic enzyme, AT-4, ARTC1 / m, B7H4, BAGE-1, BCL-2, bcr / abl, β-catenin / m, BING-4, BRCA1 / m, BRCA2 / m, CA15-3 / CA27-29, CA 19-9, CA72-4, CA125, calreticulin, CAMEL, CASP-8 / m, cathepsin B, cathepsin L, CD19, CD20, CD22, CD25, CDE30, CD33, CD4, CD52, CD55, CD56, CD80, CDC27 / m, CDK4 / m, CDKN2A / m, CEA, CLCA2, CML28, CML66, COA-1 / m, coactosin-like protein, collagen XXIII XXIII), COX-2, CT-9 / BRD6, Cten, Cyclin B1, Cyclin D1, cyp-B, CYPB1, DAM-10, DAM-6, DEK-CAN, EFTUD2 / m, EGFR, ELF2 / m, EMMPRIN, EpCam, EphA2, EphA3, ErbB3, ETV6-AML1, EZH2, FGF-5, FN, Frau-1, G250, GAGE-1, GAGE-2, GAGE-3, GAGE-4, GAGE-5, GAGE-6, GAGE7b, GAGE-8, GDEP, GnT-V, gp100, GPC3, GPNMB / m, HAGE, HAST-2, hepsin, Her2 / neu, HERVK-MEL, HLA-A*0201 - R1 7I, HLA-A1 1 / m, HLA-A2 / m, HNE, Homeobox NKX3.1, HOM-TES-14 / SCP-1, HOM-TES-85, HPV-E6, HPV-E7, HSP70-2M, HST-2, hTERT, iCE, IGF-1R, IL-13Ra2, IL-2R, IL-5, Immature Laminin Receptor, Kallikrein-2, Kallikrein-4, i67, KIAA0205, KIAA0205 / m, KK-LC-1. K-Ras / m, LAGE-A1, LDLR-FUT, MAGE-A1, MAGE-A2, MAGE-A3, MAGE-A4, MAGE-A6, MAGE-A9, MAG E-A10, MAGE-A12, MAGE-B1, MAGE-B2, MAGE-B3, MAGE-B4, MAGE-B5, MAGE-B6, MAGE-B10, MAGE-B1 6. MAGE-B1 7. MAGE-C1, MAGE-C2, MAGE-C3, MAGE-D1, MAGED2, MAGE-D4, MAGE-E1, MAGE-E2, MAGE-F1, MAGE-H I, MAGEL2, Mammaglobulin A, MART-1 / Melan-A, MART-2, MART-2 / m, matrix protein 22, MC1 R, M-CSF, ME 1 / m, mesothelin, MG50 / PXDN, MMP1 1, MN / CA IX-antigen, MRP-3, MUC-1, MUC-2, MUM-1 / m, MUM-2 / m, MUM-3 / m, myosin I / m type, NA88-A, N-acetylglucosamine transferase-V, neo-PAP, neo-PAP / m, NFYC / m, NGEP, NMP22, NPM / ALK, N-Ras / m, NSE, NY-ESO-1, NY-ESOB, OA1, OFA-iLRP, OGT, OGT / m, OS-9, OS-9 / m, osteocalcin, osteopontin, p190 minor bcr-abl, p53, p53 / m, PAGE-4, PAI-1, PAI-2, PAP, PART-1, PATE, PDEF, Pim-1 kinase, Pin-1, Pml / PARα, POTE, PRAME, PRDX5 / m, prostate-specific protein (Prostein), protease-3, PSA, PSCA, PSGR, PSM, PSMA, PTPRK / m, RAGE-1, RBAF600 / m, RHAMM / CD1 68, RU1, RU2, S-100, SAGE, SART-1, SART-2, SART-3, SCC, SIRT2 / m, Sp1 7. SSX-1, SSX-2 / HOM-MEL-40, SSX-4, STAMP-1, STEAP-1, Survivin, Survivin-2B, SYT-SSX-1, SYT-SSX-2, TA-90, TAG-72, TARP, TEL-AML1, TGF-β, TGF-βRII, TGM-4, TPI / m, TRAG-3, TRG, TRP-1, TRP-2 / 6b, TRP / INT2, TRP-p8, tyrosinase, UPA, VEGFR1, VEGFR-2 / FLK-1, WT1, and immunoglobulin genotypes of lymphocytes or T cell receptor genotypes of lymphocytes, or homologs, fragments, variants, or derivatives of the above-mentioned tumor antigens.

[0072] In the present invention, tumor antigens are selected from, but are not limited to, a group consisting of: NY-ESO-1, HER-2 / neu, MAGE-1, tyrosinase, MUC1, CEA, Mam-A, hTERT, Syalyl-Tn, WT1, α-fetoprotein, CA-125, gp-100, p53 , Ras, Src, EGFRvIII, PSMA, GD2, Bcr-abl, survivin, PSA, EphA2, PAP, AFP, EpCAM, ALK, mesothelin, PSCA, MART-1, Melan-A, SCP-1, SPAG9, AKAP4, and OY-TES-1.

[0073] In the present invention, the pathogenic antigen may be selected from a group consisting of bacterial, viral, fungal and protozoan antigens.

[0074] In the present invention, pathogenic antigens may be derived from influenza viruses or respiratory syncytial viruses virus, RSV), coronavirus, herpes simplex virus (HSV), human papillomavirus (HPV), human immunodeficiency virus (HIV), Plasmodium spp., Staphylococcus aureus, dengue virus, Chlamydia trachomatis, cytomegalovirus (CMV), hepatitis B virus (HBV), Mycobacterium tuberculosis, rabies virus, and any derivative of the xanthovirus, or any derivative of the above, protein variants, or proteomorphic viruses,

[0075] In the present invention, an antigenic polypeptide or immunogenic protein thereof is an influenza virus antigenic polypeptide, which is at least one selected from, but not limited to, a group consisting of: defined antigenic subdomains of hemagglutinin (HA), also known as HA1 , HA2 or a combination of HA1 and HA2, and neuraminidase (NA), nuclear protein (NP), matrix protein 1 (M1), matrix protein 2 (M2), nonstructural protein 1 (NS1) and nonstructural protein 2 (NS2).

[0076] In the present invention, an influenza virus antigenic polypeptide may be, but is not limited to, an immunogenic fragment of influenza hemagglutinin 1 (HA1), hemagglutinin 2 (HA2) or HA1 or HA2.

[0077] In this invention, the influenza antigenic polypeptide or its immunogenic protein is derived from an influenza virus strain selected from the group consisting of influenza B Yamagata virus, influenza B Victoria virus, influenza A H3N2 virus and influenza A H1N1 virus, more preferably from the HA protein of each virus strain, but not limited thereto.

[0078] In this invention, the polynucleotide encoding the influenza antigen polypeptide or its immunogenic protein may be codon-optimized, preferably any of the sequences represented by SEQ ID No. 55 to 66, but not limited thereto.

[0079] In this invention, the polynucleotide encoding the 5'-UTR and the signal peptide; and the polynucleotide encoding the antigenic polypeptide or its immunogenic protein are selected from, but not limited to, any one of the following: (i) polynucleotide encoding the 5'-UTR of SEQ ID NO: 1 and the signal peptide of SEQ ID NO: 39; and polynucleotide encoding the antigenic polypeptide or its immunogenic protein of SEQ ID NO: 55; (ii) polynucleotide encoding the 5'-UTR of SEQ ID NO: 1 and the signal peptide of SEQ ID NO: 42; and polynucleotide encoding the antigenic polypeptide or its immunogenic protein of SEQ ID NO: 58; (iii) polynucleotide encoding the 5'-UTR of SEQ ID NO: 1 and the signal peptide of SEQ ID NO: 45; and polynucleotide encoding the antigenic polypeptide or its immunogenic protein of SEQ ID NO: 61; (iv) polynucleotide encoding the 5'-UTR of SEQ ID NO: 1 and the signal peptide of SEQ ID NO: 48; and polynucleotide encoding SEQ ID NO: 61; (v) Polynucleotide encoding the antigenic polypeptide or immunogenic protein of SEQ ID NO: 64; and polynucleotide encoding the 5'-UTR of SEQ ID NO: 28 and the signal peptide of SEQ ID NO: 39; and polynucleotide encoding the antigenic polypeptide or immunogenic protein of SEQ ID NO: 55; (vi) Polynucleotide encoding the 5'-UTR of SEQ ID NO: 28 and the signal peptide of SEQ ID NO: 42; and polynucleotide encoding the antigenic polypeptide or immunogenic protein of SEQ ID NO: 58; (vii) Polynucleotide encoding the 5'-UTR of SEQ ID NO: 28 and the signal peptide of SEQ ID NO: 45; and polynucleotide encoding the antigenic polypeptide or immunogenic protein of SEQ ID NO: 61; (viii) Polynucleotide encoding the 5'-UTR of SEQ ID NO: 28 and the signal peptide of SEQ ID NO: 48; and polynucleotide encoding the antigenic polypeptide or immunogenic protein of SEQ ID NO: 64; (ix) Polynucleotide encoding the 5'-UTR of SEQ ID NO: 1 and the signal peptide of SEQ ID NO: 64; and polynucleotide encoding the antigenic polypeptide or immunogenic protein of SEQ ID NO: 64; (x) A polynucleotide encoding the signal peptide of SEQ ID NO: 41; and a polynucleotide encoding the antigenic polypeptide or immunogenic protein thereof of SEQ ID NO: 57; and a polynucleotide encoding the 5'-UTR of SEQ ID NO: 1 and the signal peptide of SEQ ID NO: 44; and a polynucleotide encoding the antigenic polypeptide or immunogenic protein thereof of SEQ ID NO: 60; and a polynucleotide encoding the 5'-UTR of SEQ ID NO: 1 and the signal peptide of SEQ ID NO: 47; and a polynucleotide encoding the antigenic polypeptide or immunogenic protein thereof of SEQ ID NO: 63;And (xii) the polynucleotide encoding the 5'-UTR of SEQ ID NO: 1 and the signal peptide of SEQ ID NO: 50; and the polynucleotide encoding the antigenic polypeptide or its immunogenic protein of SEQ ID NO: 66.

[0080] In this invention, the 3'-UTR is selected from, but not limited to, the group consisting of: human α-globulin 3'-UTR; β-globulin 3'-UTR; CYBA 3'-UTR; albumin 3'-UTR; growth hormone (GH) 3'-UTR; VEEV 3'-UTR; hepatitis B virus (HBV) 3'-UTR; α-globulin 3'-UTR; DEN 3'-UTR; PAV barley yellow dwarf virus (BYDV-PAV) 3'-UTR; elongation factor 1 α1 (EEF1A1) 3'-UTR; manganese superoxide dismutase (MnSOD) 3'-UTR; β subunit (β-mRNA) of mitochondrial H(+)-ATP synthase 3'-UTR; GLUT1 3'-UTR; MEF2A 3'-UTR; β-F1-ATPase 3'-UTR; its functional fragments and their combinations.

[0081] In this invention, 3'-UTR can be represented by the sequence of SEQ ID NO: 71.

[0082] As used herein, the term "3'-UTR" generally refers to a portion of mRNA located between the protein-coding region (i.e., open reading frame, coding region) and the poly(A) sequence. The 3'-UTR of mRNA is not translated into an amino acid sequence. The 3'-UTR sequence is typically encoded by genes that are transcribed into their respective mRNAs during gene expression. This genomic sequence is first transcribed into immature mRNA, which contains optional introns. The immature mRNA is then further processed into mature mRNA during maturation. This maturation process includes steps such as 5'-capping, cleavage of immature mRNA to remove selective introns, and modifications to the 3' end (such as polyadenylation of the 3' end of immature mRNA and selective endonuclease or exonuclease cleavage).

[0083] In this invention, the 3'-UTR corresponds to the sequence at the 3' end of the stop codon in the protein-coding region of mature mRNA, preferably to the sequence immediately adjacent to the 3' end of the stop codon in the protein-coding region and extending to the 5' end of the poly(A) sequence, preferably a nucleotide immediately adjacent to the 5' end of the poly(A) sequence. The term "correspondingly" means that the 3'-UTR sequence can be an RNA sequence, such as the mRNA sequence used to define the 3'-UTR sequence, or a DNA sequence corresponding to such an RNA sequence.

[0084] In this invention, the poly(A) tail or quasi-poly(A) tail sequence further includes a poly(A) tail. In a further embodiment, a terminal group on the poly(A) tail may be introduced for stabilization. In another embodiment, the poly(A) tail includes a des-3' hydroxyl tail.

[0085] During RNA processing, a long chain of adenine nucleotides (poly(A) tail) can be added to polynucleotides (such as mRNA molecules) to increase stability. Post-transcriptionally, the 3' end of the transcript can be immediately cleaved to release the 3' hydroxyl group. Subsequently, poly-A polymerase adds the adenine nucleotide chain to the RNA. This process, known as polyadenylation, adds the poly(A) tail, which can be, for example, from about 80 to about 250 residues (including lengths of about 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, or 250 residues). The poly(A) tail can also be added after the product has flowed out of the cell nucleus.

[0086] According to the present invention, a terminal group on the poly(A) tail can be introduced for stabilization. The polynucleotides of the present invention may include a des-3' hydroxy tail. They may further include structural moieties or 2'-O-methyl modifications, as taught by Junjie Li et al. (Current Biology, Vol. 15, 1501-1507, August 23, 2005, the contents of which are incorporated herein by reference in their entirety).

[0087] The unique poly(A) tail length provides certain advantages to the polynucleotides of the present invention. Typically, if a poly(A) tail is present, its length is greater than 30 nucleotides. In other embodiments, the length of the poly(A) tail is greater than 35 nucleotides (e.g., at least about 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1,000, 1,100, 1,200, 1,300, 1,400, 1,500, 1,600, 1,700, 1,800, 1,900, 2,000, 2,500 and more than 3,000 nucleotides).

[0088] In some embodiments, the polynucleotide or a region thereof comprises about 30 to about 3,000 nucleotides (e.g., 30 to 50, 30 to 100, 30 to 250, 30 to 500, 30 to 750, 30 to 1,000, 30 to 1,500, 30 to 2,000, 30 to 2,500, 50 to 100, 50 to 250, 50 to 500, 50 to 750, 50 to 1,000, 50 to 1,500, 50 to 2,000, 50 to 2,500, 50 to 3,000, 100 to 500, 100 to 750, 100 to 1,000, 100 to 1,500). 100 to 2,000, 100 to 2,500, 100 to 3,000, 500 to 750, 500 to 1,000, 500 to 1,500, 500 to 2,000, 500 to 2,500, 500 to 3,000, 1,000 to 1,500, 1,000 to 2,000, 1,000 to 2,500, 1,000 to 2,500, 1,000 to 3,000, 1,500 to 2,000, 1,500 to 2,500, 1,500 to 3,000, 2,000 to 2,500 and 2,500 to 3,000).

[0089] In some embodiments, the poly(A) tail is designed based on the length of the entire polynucleotide or the length of a specific region of the polynucleotide. This design can be based on the length of the coding region, the length of a specific feature or region, or the length of the final product of polynucleotide expression.

[0090] In this respect, the length of the poly(A) tail can be 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100% longer than the polynucleotide or its feature. The poly(A) tail can also be engineered to be a part of the polynucleotide to which it belongs. In this respect, the poly(A) tail can be at least 10, 20, 30, 40, 50, 60, 70, 80, or 90% of the total length of the fragment, a region of the fragment, or the total length of the fragment minus the length of the poly(A) tail. Furthermore, engineered binding sites and conjugation of the polynucleotide to the poly-A binding protein can enhance expression.

[0091] Furthermore, multiple different polynucleotides can be linked together via poly-A binding protein (PABP) using nucleotides modified at the 3' end of the poly(A) tail. Transfection experiments can be performed in suitable cell lines, and protein yield can be measured by ELISA at 12, 24, 48, 72, and 7 days post-transfection.

[0092] In some embodiments, the polynucleotides of the present invention are designed to include a poly-AG tetramer region. A G-tetramer is a cyclic hydrogen-bonded secondary structure of four guanine nucleotides, which can be formed from G-rich sequences in DNA and RNA. In this experiment, the G-tetramer was incorporated into the end of the poly(A) tail. The stability, protein yield, and other parameters, including half-life at different time points, of the resulting polynucleotides were tested. It was found that the poly-AG tetramer resulted in a protein yield from mRNA equivalent to at least 75% of the protein yield obtained using the 120-nucleotide poly(A) tail alone.

[0093] In this invention, the poly(A) tail sequence can be any nucleic acid sequence capable of performing poly(A) tail functions, and its characteristic is preferably that one or more nucleotides selected from the group consisting of uracil (U), cytosine (C) and guanine (G), other than adenine, are inserted between a plurality of adenines or at the end of the poly(A) tail, but is not limited thereto.

[0094] In this invention, the mRNA construct may include one or more backbone-modified, sugar-modified or base-modified nucleic acids, but is not limited thereto.

[0095] Sugar Modification:

[0096] Modified nucleosides or nucleotides that may be incorporated into modified mRNA compounds including the mRNA sequence described herein may be modified at the sugar moiety. For example, the 2' hydroxyl group (OH) may be modified or substituted by a number of different "oxygen-containing" or "deoxygenated" substituents. Examples of "oxygen-containing" 2' hydroxyl group modifications may include, but are not limited to, alkoxy or allyloxy (-OR, e.g., R=H, alkyl, cycloalkyl, aryl, aralkyl, heteroaryl, or sugar); polyethylene glycol (PEG), -O(CH2CH2O)nCH2CH2OR; "locked" nucleic acid (LNA), wherein the 2' hydroxyl group is linked to the 4' carbon of the same ribose through, for example, a methylene crosslink; and an amino group (-O-amino, wherein the amino group, e.g., NRR, may be alkylamino, dialkylamino, heterocyclic, arylamino, diarylamino, heteroarylamino, or diheteroarylamino, ethylenediamine, polyamino) or aminoalkoxy.

[0097] "Deoxygenation" modification may include a hydrogen amino group (e.g., NH2; alkylamino group, dialkylamino group, heterocyclic group, arylamino group, diarylamino group, heteroarylamino group, diheteroarylamino group or amino acid); or the amino group may be attached to the sugar via a linker, wherein the linker includes at least one of the atoms C, N and O.

[0098] The glycosyl group may further contain one or more carbons having a stereochemical configuration opposite to that of the corresponding carbon in ribose. Therefore, the modified mRNA may include nucleotides containing sugars such as arabinose.

[0099] Skeleton Modification:

[0100] The phosphate backbone can be further modified in modified nucleosides and nucleotides, which can be incorporated into modified mRNA compounds containing the mRNA sequence described herein. The phosphate groups of the backbone can be modified by replacing one or more oxygen atoms with other substituents. Furthermore, the modified nucleosides or nucleotides can include complete replacement of the unmodified phosphate moiety with a modified phosphate ester as described herein. Examples of modified phosphate groups include, but are not limited to, phosphorothioates, phosphoroselenates, boranophosphates, borano phosphate esters, hydrogen phosphates, amino phosphates, alkyl phosphates, or arylphosphonates and triphosphates. In dithiophosphates, both unattached oxygen atoms are replaced by sulfur.

[0101] The phosphate ester linker can also be modified by replacing the linked oxygen with nitrogen (crosslinked phosphatidylamine), sulfur (crosslinked thiophosphate), or carbon (crosslinked methylene phosphonate).

[0102] Base modification:

[0103] Modified nucleosides or nucleotides that may be incorporated into modified mRNA compounds containing the mRNA sequence described herein may further be modified at the nucleobase portion. Examples of nucleobases found in mRNA include, but are not limited to, adenine, guanine, cytosine, and uracil. For example, the nucleosides or nucleotides described herein may be chemically modified at the major groove. In some embodiments, major groove chemical modifications may include amino groups, thiol groups, alkyl groups, or halogen groups.

[0104] In a particularly preferred embodiment of the present invention, the nucleotide analog / modification is preferably selected from: 2-amino-6-chloropurine nucleoside-5'-triphosphate, 2-aminopurine nucleoside-5'-triphosphate; 2-aminoadenosine-5'-triphosphate, 2'-amino-2'-deoxycytidine-triphosphate, 2-thiocytidine-5'-triphosphate, 2-thiouridine-5'-triphosphate, 2'-fluorothymidine-5'-triphosphate, 2'-O-methylinosine. -5'-triphosphate, 4-thiouridine-5'-triphosphate, 5-aminoallylcytidine-5'-triphosphate, 5-aminoallyluridine-5'-triphosphate, 5-bromocytidine-5'-triphosphate, 5-bromouridine-5'-triphosphate, 5-bromo-2'-deoxycytidine-5'-triphosphate, 5-bromo-2'-deoxyuridine-5'-triphosphate, 5-iodocytidine-5'-triphosphate, 5-iodo-2'-deoxycytidine-5'-triphosphate, 5-iodocytidine-5'-triphosphate, 5-iodocytidine-2'-deoxycytidine-5'-triphosphate, 5-iodocytidine Uridine-5'-triphosphate, 5-iodine-2'-deoxyuridine-5'-triphosphate, 5-methylcytidine-5'-triphosphate, 5-methyluridine-5'-triphosphate, 5-propynyl-2'-deoxycytidine-5'-triphosphate, 5-propynyl-2'-deoxyuridine-5'-triphosphate, 6-azacytidine-5'-triphosphate, 6-azauridine-5'-triphosphate, 6-chloropurine nucleoside-5'-triphosphate, 7-deazaadenosine-5'-triphosphate Ester, 7-deazaguanosine-5'-triphosphate, 8-azaadenosine-5'-triphosphate, 8-azidoadenosine-5'-triphosphate, benzimidazole-nucleoside-5'-triphosphate, N1-methyladenosine-5'-triphosphate, N1-methylguanosine-5'-triphosphate, N6-methyladenosine-5'-triphosphate, O6-methylguanosine-5'-triphosphate, pseudouridine-5'-triphosphate, or puromycin-5'-triphosphate, flavin-5'-triphosphate.

[0105] Particularly preferred are base-modified nucleotides selected from the group consisting of nucleotides whose bases are modified: 5-methylcytidine-5'-triphosphate, 7-deazine-guanosine-5'-triphosphate, 5-bromocytidine-5'-triphosphate and pseudouridine-5'-triphosphate.

[0106] In some embodiments, the modified nucleosides include 5-pyridin-4-ketoribonucleotide, 5-aza-uridine, 2-thio-5-aza-uridine, 2-thiouridine, 4-thio-pseudouridine, 2-thio-pseudouridine, 5-hydroxyuridine, 3-methyluridine, 5-methoxyuridine, 5-carboxymethyluridine, 1-carboxymethyl-pseudouridine, 5-propynyluridine, 1-propynyl-pseudouridine, 5-tauronicomethyluridine, 1-tauronicomethyl-pseudouridine, 5-tauronicomethyl-2-thiouridine. Uro-uridine, 1-taurylmethyl-4-thio-uridine, 5-methyl-uridine, 1-methyl-pseudouridine, 4-thio-1-methyl-pseudouridine, 2-thio-1-methyl-pseudouridine, 1-methyl-1-deazino-pseudouridine, 2-thio-1-methyl-1-deazino-pseudouridine, dihydrouridine, dihydropseudouridine, 2-thio-dihydrouridine, 2-thio-dihydropseudouridine, 2-methoxyuridine, 2-methoxy-4-thio-uridine, 4-methoxy-pseudouridine and 4-methoxy-2-thio-pseudouridine.

[0107] In some embodiments, the modified nucleosides include 5-aza-cytidine, pseudocytidine, 3-methylcytidine, N4-acetylcytidine, 5-methcytidine, N4-methylcytidine, 5-hydroxymethylcytidine, 1-methyl-methcytidine, pyrrole-cytidine, pyrrole-pseudocytidine, 2-thiocytidine, 2-thio-5-methylcytidine, 4-thio-pseudocytidine, 4-thio-1-methyl-pseudocytidine, 4- Thio-1-methyl-1-deaza-pseudoisocytidine, 1-methyl-1-deaza-pseudoisocytidine, zebularine, 5-aza-zebularine, 5-methyl-zebularine, 5-aza-2-thio-zebularine, 2-thio-zebularine, 2-methoxy-cytidine, 2-methoxy-5-methyl-cytidine, 4-methoxy-methylisocytidine, and 4-methoxy-1-methyl-pseudoisocytidine.

[0108] In other embodiments, the modified nucleosides include 2-aminopurine, 2,6-diaminopurine, 7-deaza-adenine, 7-deaza-8-aza-adenine, 7-deaza-2-aminopurine, 7-deaza-8-aza-2-aminopurine, 7-deaza-2,6-diaminopurine, 7-deaza-8-aza-2,6-diaminopurine, 1-methyladenosine, N6- Methyl adenosine, N6-isopentenyl adenosine, N6-(cis-hydroxyisopentenyl) adenosine, 2-methylthio-N6-(cis-hydroxyisopentenyl) adenosine, N6-glycinylaminomethyladenosine, N6-threonylaminomethyladenosine, 2-methylthio-N6-threonylaminomethyladenosine, N6,N6-dimethyl adenosine, 7-methyl adenosine, 2-methylthio-adenosine, and 2-methoxy-adenosine.

[0109] In other embodiments, the modified nucleosides include inosine, 1-methyl-inosine, wyosine, wybutosine, 7-deazino-guanosine, 7-deazino-8-aza-guanosine, 6-thio-guanosine, 6-thio-7-deazino-guanosine, 6-thio-7-deazino-8-aza-guanosine, 7-methyl-guanosine, 6-thio-7-methyl-guanosine, 7-methylinosine, 6-methoxy-guanosine, 1-methyl-guanosine, N2-methyl-guanosine, N2,N2-dimethyl-guanosine, 8-sideoxy-guanosine, 7-methyl-8-sideoxy-guanosine, 1-methyl-6-thio-guanosine, N2-methyl-6-thio-guanosine, and N2,N2-dimethyl-6-thio-guanosine.

[0110] In some embodiments, the nucleotide may be modified at the major groove and may include a hydrogen at C-5 of uracil replaced by a methyl or halogen group. In some embodiments, the modified nucleoside is 5'-O-(1-thiophosphate)-adenosine, 5'-O-(1-thiophosphate)-cytidine, 5'-O-(1-thiophosphate)-guanosine, 5'-O-(1-thiophosphate)-uridine, or 5'-O-(1-thiophosphate)-pseuuridine.

[0111] In other specific embodiments, the modified mRNA may include nucleoside modifications selected from the following: 6-aza-cytidine, 2-thio-cytidine, α-thio-cytidine, pseudo-iso-cytidine, 5-aminoallyl-uridine, 5-iodo-uridine, N1-methyl-pseudo-uridine, 5,6-dihydrouridine, α-thio-uridine, 4-thio-uridine, 6-aza-uridine, 5-hydroxy-uridine, deoxy-thymidine 5-Methyl-uridine, pyrrolidin-cytidine, inosine, α-thio-guanosine, 6-methyl-guanosine, 5-methyl-cytidine, 8-sideoxy-guanosine, 7-deazido-guanosine, N1-methyl-adenosine, 2-amino-6-chloro-purine, N6-methyl-2-amino-purine, pseudo-iso-cytidine, 6-chloro-purine, N6-methyl-adenosine, α-thio-adenosine, 8-azido-adenosine, and 7-deazido-adenosine.

[0112] On the other hand, the present invention relates to an influenza vaccine composition comprising an mRNA construct.

[0113] As used in this invention, "vaccine" is generally understood to be a prophylactic or therapeutic substance that provides at least one antigen, preferably an antigenic peptide or protein. "Providing at least one antigen" means, for example, that the vaccine includes an antigen or that the vaccine includes, for example, a molecule encoding an antigen. Therefore, it is particularly contemplated that the vaccines of the present invention include at least one synthetic nucleic acid (RNA) molecule encoding at least one antigenic peptide (polypeptide) or protein as defined herein, which may be derived from, for example, tumor antigens, bacterial, viral, fungal or protozoan antigens, autoantigens, allergens or allogeneic antigens, and when expressed and presented to the immune system, preferably induces an immune response against the corresponding antigen. However, synthetic nucleic acid (RNA) molecules encoding non-antigenic peptides (polypeptides) or proteins of interest may also be used in the vaccines of the present invention.

[0114] In this invention, the mRNA construct of the vaccine composition may be compounded with one or more lipids to form lipid nanoparticles or liposomes.

[0115] Lipid nanoparticles may include, but are not limited to, cationic lipids, PEG-modified lipids, sterols and non-cationic lipids.

[0116] In this invention, the mRNA construct can be provided in a complex form, i.e., in a form complexed or associated with one or more (poly)cationic compounds, preferably (poly)cationic polymers, (poly)cationic peptides, or proteins, such as protamine, (poly)cationic polysaccharides, and / or (poly)cationic lipids. In this regard, the terms "complex" or "associated" refer to an intrinsically stable combination of at least one synthetic nucleic acid (RNA) molecule with one or more of the above-described compounds in a larger complex or element, without covalent linkage.

[0117] Lipids

[0118] According to a preferred embodiment, the mRNA construct of the present invention is complexed or conjugated with lipids (particularly cationic and / or neutral lipids) to form one or more lipid nanoparticles or liposomes. Therefore, in some embodiments, the synthetic nucleic acid (RNA) molecules of the present invention can be provided in the form of lipid-based formulations (particularly liposomes comprising synthetic nucleic acid (RNA) molecules and / or lipid nanoparticles).

[0119] Lipid nanoparticles

[0120] According to some preferred embodiments, the mRNA construct of the present invention is complexed or conjugated with lipids (especially cationic and / or neutral lipids) to form one or more lipid nanoparticles.

[0121] Preferably, the lipid nanoparticles (LNPs) may include: (a) at least one mRNA complex of the present invention, (b) cationic lipids, (c) aggregation reducing agents (e.g., polyethylene glycol (PEG) lipids or PEG-modified lipids), (d) optional non-cationic lipids (e.g., neutral lipids), and (e) optional sterols.

[0122] In some embodiments, in addition to at least one mRNA construct of the present invention, LNP further includes (i) at least one cationic lipid; (ii) neutral lipid; (iii) sterol, for example, cholesterol; and PEG-lipid, which may be included in a molar ratio of about 20-60% cationic lipid: 5-25% neutral lipid: 25-55% sterol; 0.5-15% polyethylene glycol lipid.

[0123] In some embodiments, the mRNA constructs of the present invention can be formulated into amino alcohol lipids. The amino alcohol lipids used in the present invention can be prepared by the method described in U.S. Patent No. 8,450,298, the entire contents of which are incorporated herein by reference.

[0124] Liposomes

[0125] In some embodiments, the mRNA construct of the present invention is formulated into liposomes. Liposomes based on cationic lipids can form complexes with negatively charged nucleic acids (e.g., RNA) through electrostatic interactions, thereby producing complexes that offer biocompatibility, low toxicity, and the potential for large-scale production required for in vivo clinical applications. Liposomes can be fused to the plasma membrane for uptake; in the cell, liposomes are processed via phagocytosis, and the nucleic acids are subsequently released from the endosome / carrier into the cytoplasm. Assuming that liposomes are essentially analogs of biological membranes and can be prepared from natural and synthetic phospholipids, liposomes have long been considered drug delivery carriers due to their excellent biocompatibility.

[0126] Liposomes typically consist of a lipid bilayer, which may be composed of cationic, anionic, or neutral (phospholipid) lipids and cholesterol, surrounding an aqueous core. Both the lipid bilayer and the aqueous space may contain hydrophobic or hydrophilic compounds. Liposomes may have one or more lipid membranes. Liposomes may be monolayered (referred to as monolayers) or multilayered (referred to as multilayers).

[0127] In vivo, the properties and behavior of liposomes can be altered to provide steric stability by adding a hydrophilic polymer coating, such as polyethylene glycol (PEG), to the surface of the liposomes. Furthermore, liposomes can be used for specific targeting by attaching ligands (e.g., antibodies, peptides, and carbohydrates) to their surface or to the ends of the attached PEG chains.

[0128] Liposomes typically exist in the form of spherical vesicles, ranging in size from 20 nm to several micrometers. Liposome sizes can vary, including but not limited to multilayered vesicles (MLVs) with diameters ranging from hundreds of nanometers and comprising a series of concentric bilayers separated by narrow aqueous compartments; small single-celled vesicles (SUVs) with diameters less than 50 nm; and large single-layered vesicles (LUVs) with diameters between 50 and 500 nm. Liposome design may include, but is not limited to, opsonins or ligands to improve liposome attachment to unhealthy tissues or to initiate events such as, but not limited to, endocytosis. Liposomes may include low or high pH values ​​to enhance drug delivery.

[0129] In this invention, the vaccine composition may further include one or more adjuvants or activators.

[0130] In the broadest sense, "adjuvant" or "adjuvant ingredient" is generally a pharmacologically and / or immunological agent that can modify (e.g., enhance) the potency of another active agent (e.g., a therapeutic agent or vaccine). In this context, "adjuvant" can be understood as any compound suitable for supporting the administration and delivery of the vaccine compositions of the present invention. Specifically, adjuvants may preferably enhance the immunostimulatory properties of the vaccine to which they are added. Furthermore, such adjuvants may elicit or amplify an immune response of the innate immune system, i.e., a nonspecific immune response, without binding to it.

[0131] "Adjuvants" generally do not elicit adaptive immune responses. To date, "adjuvants" have not been used as antigens either. That is, when administered, the vaccines of the present invention typically elicit adaptive immune responses due to antigenic peptides or proteins encoded by at least one coding sequence of a synthetic nucleic acid (RNA) molecule contained in the vaccine.

[0132] Suitable adjuvants may be selected from any adjuvant known to those skilled in the art and applicable to the present invention, i.e., drugs that help induce an immune response in mammals, such as TDM, MDP, cell wall dipeptide, pluronic, vitiligo solution, aluminum hydroxide, ADJUMER™ (polyphosphazene); aluminum phosphate gel; dextran from algae; algamulin; aluminum hydroxide gel (vitiligo); highly protein-adsorbing aluminum hydroxide gel; low-viscosity aluminum hydroxide gel; low-viscosity aluminum hydroxide gel; AF or SPT (squalane emulsion (5%), Tween 80 (0.2%), fluoride ion L121 (1.25%), phosphate-buffered saline (pH 7.4); AVRIDINE™ (propylenediamine); a group of substances corresponding to pathogen-associated molecular patterns (PAMPs) that react with pattern recognition receptors (PRRs); CpG DNA; lipoproteins; flagella; poly(I:C); saponins; squalene; decanoic acid glyceride; 3D-MPL; or detoxified lipooligosaccharides (dLOS).

[0133] On the other hand, the present invention relates to the use of vaccine compositions for the prevention of influenza.

[0134] As used herein, “influenza” refers to an infectious disease caused by the influenza virus and may be used interchangeably with pandemic cold, circulating cold, or influenza (FLU).

[0135] As used herein, “prevention” means any action that suppresses or delays the development of influenza by administering the vaccine composition of the present invention.

[0136] On the other hand, the present invention relates to a method for preventing influenza, which includes the step of administering a vaccine composition.

[0137] On the other hand, the present invention relates to the use of vaccine compositions in the preparation of agents for the prevention of influenza.

[0138] Example

[0139] The present invention will be described in more detail with reference to the following embodiments. These embodiments are intended to illustrate the invention only, and it will be apparent to those skilled in the art that the scope of the invention should not be construed as limited to these embodiments.

[0140] Example 1. Preparation of mRNA construct

[0141] 1-1 Preparation of mRNA sequence

[0142] Thirty-three 5'-UTRs were screened using the method of PCT / KR2022 / 019491, and another 5'-UTR of SEQ ID NO: 1 was selected as the 5'-UTR sequence for HA protein expression (Table 3).

[0143] Furthermore, based on the wild-type Yamagata, Victoria, H3N2, and H1N1 signal sequences (SEQ ID NO: 51, 52, 53, and 54, respectively) and ORF sequences (SEQ ID NO: 67, 68, 69, and 70, respectively) listed in Table 3, the signal sequence and ORF sequence for each strain were prepared through codon optimization. In addition, signal sequences of wild-type strains with codon-optimized IgE or tPA replacements were also prepared.

[0144] [Table 3] Sequence ID NO. name sequence 1 GC00 AGGAGGACUGGACUGGACUGGACUGCCACC 2 GC01 AGGAGAAGAGAGAAAAGUAAAAUAGCCACC 15 GC14 AGGAGAACUAGUACCCACCCGACAGCCACC 28 GC27 RAINCACCACCCACCACC 30 GC29 HEADWATERWATERWATERCACCACC 35 B_Now_UTR_WT AGCAGACACAAA 36 B_Vic_UTR_WT AGCAGACACAAA 37 A_H3N2_UTR_WT AGCAAAAGCAGGGGAUAAUUCUAUUAACC 38 A_H1N1_UTR_WT AGCAAAAGCAGGGGAAAAUAAAAAGCAAAAAAA 39 B_No_Sig_WT AUGAAGGCCAUAAUCCUCCUCAGAUGGUAGUCAUCGAAUGCC 40 B_Ya_Sig_IgE AUGGACUGCACCUUUUCCUUAGCCGCGGCGAACGAGAGUUCUCU 41 B_Y_Sig_tPA AUGGACGCAAUGAAAAGGGGAUUGUGCUGCGUGCUGCCUGUGCGGAGCCGUGUUUGUUCCGC 42 B_Vic_Sig_WT AUGAAGGCAUUCAUGUUGUGCUGGUGGUCACGUCGAACGCU 43 B_Vic_Sig_IgE AUGGACUGGACGUGCUUAUUCCCGUGGCCUGCCACCCGCGUUCCACUCG 44 B_Vic_Sig_tPA AUGGACGCUAUGAAGCGGGGGCUAUGUUGCGUGCUCUUUGUGGCGUGCGGGUGUUCGUGUCGGCA 45 A_H3N2_Sig_WT AUGAAGAGACCAUUAUUGCCCUCUCCUACAUCUUGGCCUUGGUAUUCGCU 46 A_H3N2_Sig_IgE AUGGAUUGGACAUGGAUACUGUUCCUAGUGGGCAGCCGCAACUGCGUUCACUCCC 47 A_H3N2_Sig_tPA AUGGACGCCAUGAAAAGGGGCCUGCGUCUUGUGUGCUUGUGCUGUUUUCGUCAGUGCC 48 A_H1N1_Sig_WT AUGAAAGCUAUCCUCCGUAGUUAUGCUGUACACGUUCACCCACGGCCAAUGCA 49 A_H1N1_Sig_IgE AUGGAAUUGGACAUGGAUUCUCUCGUAGCAGCUGCUACACGUGUUCACUCA 50 A_H1N1_Sig_tPA AUGGAUGCGAUGAAGCGCGGAUUGUGCUGCGUACUGCUGCUCUGCGGAGCCGUUUUUGUUAGCGCG 51 B_Ya_Sig_WT_C AUGAAGGCAAUAAUUGUACUACUCAUGUAGUACAUCCAACGCA 52 B_Vic_Sig_WT_C AUGAAGGCAAUAAUUGUACUACUCAUGGUAGUACAUCCAAUGCA 53 A_H3N2_Sig_WT_C AUGAAGACAUACAUUGCUUUGAGCUACAUUCUAUGUCUAUGCUUGUUUUCGCU 54 A_H1N1_Sig_WT_C AUGAAGGCAAUACUAGUAGUUAUGCUGUAUACAUUACAACCGCAAAUGCA 55 B_Ya_HA_WT 56 B_Yes_to_IgE 57 B_Ya_HA_tPA 58 B_Vic_HA_WT 59 B_Vic_HA_IgE 60 B_Vic_HA_tPA 61 A_H3N2_HA_WT 62 A_H3N2_HA_IgE 63 A_H3N2_HA_tPA 64 A_H1N1_HA_WT 65 A_H1N1_HA_IgE 66 A_H1N1_HA_tPA 67 B_Ya_HA_WT_C 68 B_Vic_HA_WT_C 69 A_H3N2_HA_WT_C 70 A_H1N1_HA_WT_C 71 3'-UTR UAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGC

[0145] Information on the mRNA generated for in vivo protein expression assays is shown in Tables 4 to 7 below.

[0146] [Table 4] Influenza B strains in Yamagata name 5'-UTR Sequence ID NO. signal peptides Sequence ID NO. ORF Sequence ID NO. 3'-UTR Sequence ID NO. Poly(A) tail GC00_WT_HA 1 39 55 71 120 bp GC01_WT_HA 2 39 55 71 120 bp GC14_WT_HA 15 39 55 71 120 bp GC27_WT_HA 28 39 55 71 120 bp GC29_WT_HA 30 39 55 71 120 bp GC00_IgE_HA 1 40 56 71 120 bp GC01_IgE_HA 2 40 56 71 120 bp GC14_IgE_HA 15 40 56 71 120 bp GC27_IgE_HA 28 40 56 71 120 bp GC29_IgE_HA 30 40 56 71 120 bp GC00_tPA_HA 1 41 57 71 120 bp GC01_tPA_HA 2 41 57 71 120 bp GC14_tPA_HA 15 41 57 71 120 bp GC27_tPA_HA 28 41 57 71 120 bp GC29_tPA_HA 30 41 57 71 120 bp control group 35 51 67 71 120 bp

[0147] [Table 5] Influenza B strains in Victoria name 5'-UTR Sequence ID NO. signal peptides Sequence ID NO. ORF Sequence ID NO. 3'-UTR Sequence ID NO. Poly(A) tail GC00_WT_HA 1 42 58 71 120 bp GC01_WT_HA 2 42 58 71 120 bp GC14_WT_HA 15 42 58 71 120 bp GC27_WT_HA 28 42 58 71 120 bp GC29_WT_HA 30 42 58 71 120 bp GC00_IgE_HA 1 43 59 71 120 bp GC01_IgE_HA 2 43 59 71 120 bp GC14_IgE_HA 15 43 59 71 120 bp GC27_IgE_HA 28 43 59 71 120 bp GC29_IgE_HA 30 43 59 71 120 bp GC00_tPA_HA 1 44 60 71 120 bp GC14_tPA_HA 15 44 60 71 120 bp GC27_tPA_HA 28 44 60 71 120 bp control group 36 52 68 71 120 bp

[0148] [Table 6] Influenza A (H3N2) strains Name 5'-UTR Sequence ID NO. signal peptides Sequence ID NO. ORF Sequence ID NO. 3'-UTR Sequence ID NO. Poly(A) tail GC00_WT_HA 1 45 61 71 120 bp GC01_WT_HA 2 45 61 71 120 bp GC14_WT_HA 15 45 61 71 120 bp GC27_WT_HA 28 45 61 71 120 bp GC29_WT_HA 30 45 61 71 120 bp GC00_IgE_HA 1 46 62 71 120 bp GC14_IgE_HA 15 46 62 71 120 bp GC27_IgE_HA 28 46 62 71 120 bp GC29_IgE_HA 30 46 62 71 120 bp GC00_tPA_HA 1 47 63 71 120 bp GC14_tPA_HA 15 47 63 71 120 bp GC27_tPA_HA 28 47 63 71 120 bp control group 37 53 69 71 120 bp

[0149] [Table 7] H1N1 Influenza Strains name 5'-UTR Sequence ID NO. signal peptides Sequence ID NO. ORF Sequence ID NO. 3'-UTR Sequence ID NO. Poly(A) tail GC00_WT_HA 1 48 64 71 120 bp GC01_WT_HA 2 48 64 71 120 bp GC14_WT_HA 15 48 64 71 120 bp GC27_WT_HA 28 48 64 71 120 bp GC29_WT_HA 30 48 64 71 120 bp GC01_IgE_HA 2 49 65 71 120 bp GC14_IgE_HA 15 49 65 71 120 bp GC29_IgE_HA 30 49 65 71 120 bp GC00_tPA_HA 1 50 66 71 120 bp GC01_tPA_HA 2 50 66 71 120 bp GC14_tPA_HA 15 50 66 71 120 bp GC27_tPA_HA 28 50 66 71 120 bp GC29_tPA_HA 30 50 66 71 120 bp Control group 38 54 70 71 120 bp

[0150] 1-2. mRNA synthesis and purification

[0151] The mRNA constructs in Tables 4 to 7 prepared in Example 1.1 according to the method described in PCT / KR2022 / 019491 were purified by in vitro transcription.

[0152] Specifically, IVT was performed under the conditions in Table 8. After the reaction was completed, template DNA was removed by treating 1 U of deoxyribonuclease I with 1 μg of DNA and reacting at 37°C for 15-30 min. The IVT product was purified using the manufacturer’s method with the Invitrogen’s MEGAclear™ kit (Austin, Texas).

[0153] [Table 8] Element volume ATP, CTP, GTP, N1-methyl pseudoUTP (final 10mm) 20 μL each Ribonuclease inhibitors 5μL Pyrophosphatase, inorganic (yeast) 0.5μL 100mm Clean Cap AG (3' OMe) 6μL Template DNA 6 μg 10X T7 polymerase reaction buffer 20μL T7 RNA polymerase 11.8μL Nuclease-free water Up to 200μL total 200μL

[0154] Example 2. Preparation of mRNA-LNP complex

[0155] Ionic lipids, phospholipids, cholesterol, and PEG-lipid conjugates were dissolved in ethanol at a molar ratio of 50:10:3 8.5:1.5 and mixed with citrate buffer (pH 4, 50 mM) containing dissolved mRNA at a volume ratio of 1:3. MC3 (MedChemExpress, USA) was used as the ionic lipid, DSPC (Avanti Polar Lipids, USA) as the phospholipid, cholesterol (Sigma Aldrich, USA) as the cholesterol, and 1,2-dimyristyl-rac-glycerol-3-methoxy polyethylene glycol-2000 (DMG-PEG 2000) (Avanti Polar Lipids, USA) as the PEG-lipid conjugate.

[0156] To generate lipid nanoparticles (LNPs), ionic lipids and mRNA were mixed using NanoAssemblr Ignite™ (Precision Nanosystems, Inc., Canada) at a total flow rate (TFR) of 12 mL / min to achieve a nitrogen-to-phosphorus ratio (N / P ratio) of 4. MWCO 10 kDa (Millipore, USA) was ethanol-removed, buffer-exchanged, and concentrated using the Amicon ultracentrifugation screening program, and then diluted, concentrated, and exchanged using 1X DPBS (Thermo Scientific, USA) to prepare the lipid nanoparticles. For cryopreservation, a final 300 mL sucrose solution was added as a cryoprotectant and the mixture was frozen (-80°C).

[0157] Example 3. Confirmation of mRNA construct performance in animal experiments

[0158] 3-1. Method for injecting mRNA constructs into animals and harvesting tissues for HA expression.

[0159] Six- to seven-week-old female Balb / c mice (OrientBio, South Korea) were purchased and housed under specific pathogen-free conditions. The day before injection, the fur on the right leg of the mice was shaved, and 50 μL of the mRNA-LNP complex prepared in Example 2 was intramuscularly injected into the right tibialis muscle using an insulin injector. Six hours after injection, the injected right tibialis muscle was harvested, collected in 1.7 mL test tubes, and stored at -70°C until the expression level of HA protein in the muscle lysate was assessed (Figure 2).

[0160] 3-2. Methods for obtaining muscle tissue lysates

[0161] Preparation of muscle lysates for detection of HA protein in injected muscle. To obtain muscle lysates, harvested muscle tissue was placed in test tubes containing tissue lysis buffer (composition: 1x cell lysis buffer (Cell signaling technology, Cat No. #9803), protease and phosphatase inhibitor microtablets, EDTA-free 1 tablet / 10 mL, ThermoFisher scientific, Cat No. A32961) and stainless steel beads, and each tissue was then lysed using a tissue lysator.

[0162] The test tube containing the lysed tissue was centrifuged at 13,000 rpm for 10 minutes at 4°C, and the supernatant was transferred to a new 1.7 mL test tube for HA protein expression.

[0163] 3-3. Measurement of HA protein in muscle lysate

[0164] Enzyme-linked immunosorbent assay (ELISA) was performed to assess HA protein expression in muscle. ELISA was performed using an ELISA kit, and capture antibodies (Yamagata: Cat No. 11053-MM09, Victoria: Cat No. 11053-MM06, H3N2: 11056-RP01, H1N1: Cat No. SEK001) from Sinobiological were diluted in PBS (phosphate-buffered saline, Lonza, Cat No. 17-516Q) and added to ELISA plates for protein coating at a final concentration of 1 to 2 μg / mL. After incubating at 4°C for 16 to 20 hours, the ELISA plate was washed three times (wash buffer composition: 0.05% Tween-20 in PBS, Tween-20 (Sigma-Aldrich, Cat No. P1379-500 mL)), and saturated at room temperature with phosphate-buffered saline (PBS) containing 2% bovine serum albumin (bovine serum albumin: Sigma-Aldrich, Cat No. A3803-100G) for 1 hour.

[0165] The amount of protein in the previously obtained muscle hydrolysate was quantified by the bicinchoninic acid (BCA) quantification method (ThermoFisher Scientific, Cat No. 23225), and an equal amount of protein was used to measure HA protein in the muscle.

[0166] After blocking, the ELISA plate was washed three times with the same washing buffer, and the prepared muscle lysate was added to the ELISA plate and incubated at room temperature for 2 hours, followed by three washes. HA detection antibodies from Sinobiological that bind to horseradish peroxidase (HRP) or biotin (Yamagata & Victoria: Cat No. SEK-11053, H3N2: Cat No. 11056-R014B, H1N1: Cat No. SEK001) were diluted to 0.5 to 1 μg / mL in PBS containing 0.5% bovine serum albumin, and 100 μL of antibody solution was added and incubated at room temperature for 1 hour.

[0167] For H3N2, the ELISA plate was washed three times with the same washing buffer, and streptavidin-HRP (Sigma-Aldrich, Cat No. S2438-250UG) was diluted 1:5,000 in PBS containing 0.5% bovine serum albumin. 100 μL of the diluted solution was added and the plate was incubated for another 20 minutes at room temperature. The ELISA plate was then washed three times and observed for 10 minutes at room temperature with TMB (3,3',5,5'-tetramethylbenzidine) solution (ThermoFisher Scientific, Cat No. 34028). Afterward, the colorimetric reaction was terminated with stop solution (SeraCare, Cat No. 5150-0021), and absorbance was measured at 450 nm using a microdisc analyzer (VersaMax) from Moleculardeveices to compare HA protein expression in muscle.

[0168] 3-4. Methods for injecting mRNA constructs into animals and collecting serum to assess HA-specific immune responses.

[0169] Animal experiments were conducted to evaluate the immune response to the mRNA constructs. Six- to seven-week-old female Balb / c mice (OrientBio, South Korea) were purchased and housed under specific pathogen-free conditions. Intramuscular immunization was performed in the right tibialis muscle of the mice using an insulin injector, with 0.1 μg of each mRNA-LNP complex in 50 μL (Figure 7). Blood samples were collected four weeks post-immunization to obtain serum.

[0170] Allow the blood sample to clot at room temperature for 30 minutes, then centrifuge at 10,000 rpm for 10 minutes at 4°C. After centrifugation, transfer the supernatant to a new 1.7 mL test tube and store at -20°C until humoral immune response is detected.

[0171] 3-5. Measurement of HA antigen-specific IgG antibody values

[0172] Enzyme-linked immunosorbent assay (ELISA) was performed to determine the titer of HA antigen-specific IgG in serum. Influenza A / H1N1 virus split vaccine was diluted in PBS and added to an ELISA plate for protein coating. After incubation at 4°C for at least 12 hours, the plate was washed three times with phosphate-buffered saline (PBS) containing 0.05% Tween-20 and saturated with PBS containing 2% bovine serum albumin (BSA Sigma, Cat No. A3803) at room temperature for 1 hour. After blocking, the ELISA plate was washed three times, and a serum sample diluted 2,000-fold in PBS containing 2% bovine serum albumin was added to the plate and incubated at room temperature for 2 hours. The plate was then washed three times and incubated with horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG antibody (Southern Biotech, Cat No. 1031-05) at room temperature for 1 hour. The ELISA plate was then washed three times and observed using TMB (3,3',5,5'-tetramethylbenzidine, ThermoFisher Scientific, Cat No. 34028) for 0 minutes. After observation, stop solution (SeraCare, Cat No. 5150-0021) was added to terminate the colorimetric reaction, and the optical density was measured at 450 nm using a microdisk analyzer (VersaMax) from Moleculardeveices.

[0173] Example 4. Comparison of HA expression in influenza B virus / Yamagata strain based on 5'UTR and signal sequence variations.

[0174] In order to enhance the immunogenicity of the mRNA construct, an ELISA assay was performed using the method of Example 3 to compare the mRNA sequence generated in Example 1 with the sequence of the influenza virus itself.

[0175] As a result, it was found that the mRNA sequence generated in Example 1 showed higher in vivo protein expression compared with the HA sequence of the influenza B virus / Yamagata strain itself, as shown in Figure 3 (Figure 3, control group vs. each lane).

[0176] Example 5. Comparison of HA expression in influenza B virus / Victoria strain based on 5'UTR and signal sequence variations

[0177] To enhance the immunogenicity of the mRNA construct, an ELISA assay was performed using the method of Example 3 to compare the mRNA sequence generated in Example 1 with the sequence of the influenza virus itself.

[0178] The results confirmed that the mRNA sequence generated in Example 1 showed higher in vivo protein expression compared with the HA sequence of the influenza B virus / Victoria strain, as shown in Figure 4 (Figure 4, control group vs. each lane).

[0179] Example 6. Comparison of HA expression in influenza A virus / H3N2 strain based on 5'UTR and signal sequence variation.

[0180] To enhance the immunogenicity of the mRNA construct, an ELISA assay was performed using the method of Example 3 to compare the mRNA sequence generated in Example 1 with the sequence of the influenza virus itself.

[0181] As a result, it was found that the mRNA sequence generated in Example 1 showed higher in vivo protein expression compared with the HA sequence of the influenza A virus / H3N2 strain itself, as shown in Figure 5 (Figure 5, control group vs. each lane).

[0182] Example 7. Comparison of HA expression in influenza A virus / H1N1 strains based on 5'UTR and signal sequence variations.

[0183] In order to enhance the immunogenicity of the mRNA construct, an ELISA assay was performed using the method of Example 3 to compare the mRNA sequence generated in Example 1 with the sequence of the influenza virus itself.

[0184] As a result, it was found that the mRNA sequence generated in Example 1 showed higher in vivo protein expression compared with the HA sequence of the influenza A virus / H1N1 strain itself, as shown in Figure 6 (Figure 6, control group vs. each lane).

[0185] Example 8. Comparison of immune responses in influenza A virus / H1N1 strains based on 5'UTR and signal sequence changes

[0186] In order to enhance the immunogenicity of the mRNA construct, an anti-influenza specific IgG ELISA assay was performed using the method of Example 3 to compare the mRNA sequence generated in Example 1 with the sequence of the influenza virus itself.

[0187] The results confirmed that the mRNA sequence generated in Example 1 exhibited higher immunogenicity compared with the antigen of the influenza A virus / H1N1 strain, as shown in Figure 8 (Figure 8, control group vs. each lane).

[0188] Example 9. Screening for 5'UTR and signal sequence combinations with high expression and immunogenicity

[0189] Based on the results of Examples 4 to 8, combinations of 5'UTR and signaling sequences with high HA expression and high immunogenicity in vivo were screened. The criteria were defined as follows: the combination had HA expression at least 1.5 times higher than the control group in vivo and immunogenicity at least 3 times higher than the control group.

[0190] First, the in vivo HA expression in Examples 4 to 7 was summarized as the fold difference relative to the control group, as shown in Table 9 below. In Table 9, GC00-HA is equivalent to GC00_WT_HA, GC00-IgE is equivalent to GC00_IgE_HA, and GC00-tPA is equivalent to GC00_tPA_HA. The remaining terms can be used interchangeably.

[0191] [Table 9] project H1N1 H3N2 Yamagata Victoria control group 1.0 1.0 1.0 1.0 GC00-HA 1.6 2.2 4.3 5.5 GC01-HA 1.3 1.2 3.2 2.0 GC14-HA 1.3 1.6 3.5 4.7 GC27-HA 1.6 1.7 3.1 4.0 GC29-HA 1.9 2.6 5.3 4.5 GC14-IgE 1.1 1.2 2.2 3.5 GC29-IgE 1.1 1.2 2.8 4.0 GC00-tPA 3.6 1.7 3.8 2.8 GC14-tPA 2.6 1.5 3.2 2.1 GC27-tPA 2.0 1.2 4.3 2.1

[0192] As shown in Table 9, the combinations that showed an increase of at least 1.5 times in expression across all strains were GC00-HA, GC27-HA, GC29-HA, GC00-tPA, and GC14-tPA.

[0193] Then, in Table 10 below, the immunogenicity of the H1N1 strain of Example 8 is summarized as the multiple of difference compared with the control group.

[0194] [Table 10] project H1N1 control group 1.0 GC00-HA 3.6 GC01-HA 3.5 GC14-HA 5.4 GC27-HA 4.7 GC29-HA 2.5 GC01-IgE 1.7 GC14-IgE 1.9 GC29-IgE 1.8 GC00-tPA 4.0 GC01-tPA 4.4 GC14-tPA 2.8 GC27-tPA 3.0 GC29-tPA 3.2

[0195] As shown in Table 10, the combinations with at least 3-fold immunogenicity were found to be GC00-HA, GC01-HA, GC14-HA, GC27-HA, GC00-tPA, GC01-tPA, GC27-tPA and GC29-tPA, and among them, the combinations with at least 1.5-fold HA expression were GC00-HA (GC00_WT_HA), GC27-HA (GC27_WT_HA) and GC00-tPA (GC00_tPA_HA), which were selected as the final combinations.

[0196] Industrial Applicability

[0197] The mRNA construct according to the present invention contains a 5'-UTR polynucleotide with improved translation efficiency, which can effectively induce the expression of antigenic peptides, which is useful for vaccine development because it can be expected to increase the immunogenicity of the vaccine.

[0198] Although certain aspects of the invention have been described in detail above, it will be apparent to those skilled in the art that these specific descriptions are merely preferred embodiments and are not intended to limit the scope of the invention. Therefore, the essential scope of the invention is defined by the appended claims and their equivalents. Figure 1 is a schematic diagram of the components of an mRNA construct according to an embodiment of the invention. [Simplified Explanation of the Diagram]

[0032] Figure 2 is a schematic diagram illustrating an animal testing process according to an embodiment of the present invention.

[0033] Figure 3 shows the protein expression results of the influenza B / Yamagata HA mRNA construct prepared according to one embodiment of the present invention in mouse muscle.

[0034] Figure 4 shows the protein expression results of the influenza B / Victoria HA mRNA construct prepared according to one embodiment of the present invention in mouse muscle lysate.

[0035] Figure 5 shows the protein expression results of the influenza A / H3N2 HA mRNA construct prepared according to an embodiment of the present invention in mouse muscle lysate.

[0036] Figure 6 shows the protein expression results of the influenza A / H1N1 HA mRNA construct prepared according to an embodiment of the present invention in mouse muscle lysate.

[0037] Figure 7 is a schematic diagram illustrating an in vivo immunogenicity test process according to an embodiment of the present invention.

[0038] Figure 8 shows the anti-HA specific IgG titer after immunization with the influenza A / H1N1 HA mRNA construct prepared according to one embodiment of the present invention.

Claims

1. An mRNA construct encoding an antigenic polypeptide or an immunogenic fragment thereof, comprising: In the order from 5' to 3', a) a 5'-cap structure; b) a 5'-untranslated region (5'-UTR); c) a polynucleotide encoding a signal peptide; d) a polynucleotide encoding an influenza virus antigenic polypeptide or an immunogenic protein thereof; e) a 3'-untranslated region (3'-UTR); and f) a poly(A) tail or poly(A) tail sequence consisting of 10 to 1000 adenine (A) nucleotides, wherein the signal peptide encoded by the polynucleotides in the 5'-UTR and c) is any one of the following groups: (i) the 5'-UTR of SEQ ID NO: 1 and a signal peptide represented by an amino acid sequence selected from the group consisting of SEQ ID NO: 72, 74, and 78; (ii) the 5'-UTR of SEQ ID NO: 28 and a signal peptide represented by an amino acid sequence selected from the group consisting of SEQ ID NO: 72, 74, and 78; (iii) SEQ ID NO: 1; (iv) The 5'-UTR of SEQ ID NO: 30 and the signal peptide represented by the amino acid sequence selected from the group consisting of SEQ ID NO: 72, 74 and 78; and (v) The 5'-UTR of SEQ ID NO: 1 and the signal peptide represented by the amino acid sequence of SEQ ID NO: 81; and (v) The 5'-UTR of SEQ ID NO: 15 and the signal peptide represented by the amino acid sequence of SEQ ID NO:

81.

2. The mRNA construct as described in claim 1, wherein, The 5'-cap structure is selected from the group consisting of m7GpppAmpG, m7GpppApG and m7,3'OmeApppG.

3. The mRNA construct as described in claim 1, wherein, The polynucleotide encoding the signal peptide is codon-optimized.

4. The mRNA construct as described in claim 1, wherein, The antigenic polypeptide is an immunogenic fragment of influenza hemagglutinin 1 (HA1), hemagglutinin 2 (HA2), or HA1 or HA2.

5. The mRNA construct as described in claim 4, wherein, The antigenic polypeptide is derived from influenza virus strains selected from the group consisting of influenza B Yamagata virus, influenza B Victoria virus, influenza A H3N2 virus, and influenza A H1N1 virus.

6. The mRNA construct as described in claim 1, wherein, The polynucleotide encoding the antigenic polypeptide or its immunogenic protein is codon-optimized.

7. The mRNA construct as described in claim 6, wherein, The polynucleotide encoding the antigenic polypeptide or its immunogenic protein is selected from the group consisting of SEQ ID NO: 55, 57, 58, 60, 61, 63, 64, and 66.

8. The mRNA construct as described in claim 1, wherein, The 3'-UTR is selected from the group consisting of: α-globulin 3'-UTR; β-globulin 3'-UTR; CYBA 3'-UTR; albumin 3'-UTR; growth hormone (GH) 3'-UTR; VEEV 3'-UTR; hepatitis B virus (HBV) 3'-UTR; DEN 3'-UTR; barley yellow dwarf virus PAV (BYDV-PAV) 3'-UTR; elongation factor 1 α1 (EEF1A1) 3'-UTR; manganese superoxide dismutase (MnSOD) 3'-UTR; β unit (β-mRNA) of mitochondrial H(+)-ATP synthase 3'-UTR; GLUT1 3'-UTR; MEF2A 3'-UTR; and β-F1-ATPase 3'-UTR.

9. The mRNA construct as described in claim 8, wherein, The 3'-UTR is a sequence represented by SEQ ID NO:

71.

10. The mRNA construct as described in claim 1, wherein, The poly(A) tail sequence comprises at least one nucleotide other than adenine, selected from the group consisting of uracil (U), cytosine (C), and guanine (G), inserted between a plurality of adenines or at the end of the poly(A) tail.

11. The mRNA construct as described in claim 1, wherein, The mRNA construct includes at least one backbone-modified, sugar-modified, or base-modified nucleic acid.

12. A vaccine composition comprising the mRNA construct described in any one of claims 1 to 11.

13. The vaccine composition as claimed in claim 12, wherein, The mRNA construct is compounded with one or more lipids to form lipid nanoparticles or liposomes.

14. The vaccine composition as claimed in claim 13, wherein, The lipid nanoparticles include cationic lipids, PEG-modified lipids, sterols, and non-cationic lipids.

15. The vaccine composition as claimed in claim 12, wherein, The vaccine composition further includes one or more adjuvants or active agents.